Clinuvel Pharmaceuticals (OTCMKTS:CLVLY) Stock Price Down 4.7% – Time to Sell?

Shares of Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) dropped 4.7% during trading on Thursday . The company traded as low as $6.75 and last traded at $6.7850. Approximately 1,251 shares changed hands during mid-day trading, a decline of 61% from the average daily volume of 3,221 shares. The stock had previously closed at $7.12.

Clinuvel Pharmaceuticals Price Performance

The business’s 50-day moving average is $7.82 and its two-hundred day moving average is $7.77.

Clinuvel Pharmaceuticals Company Profile

Clinuvel Pharmaceuticals Limited is an Australian biopharmaceutical company headquartered in Melbourne, specializing in the development and commercialisation of photoprotective and phototherapeutic solutions. The company’s research centers on harnessing the skin’s natural photoprotective pathways by modulating the melanocortin system, with a view to addressing a range of skin disorders and conditions that are exacerbated by ultraviolet light exposure.

The company’s flagship product, Scenesse (afamelanotide), is the first systemic photoprotective drug approved by both the European Medicines Agency and the U.S.